Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease
Sign Up to like & getrecommendations! Published in 2022 at "Movement Disorders"
DOI: 10.1002/mds.29184
Abstract: Terazosin (TZ) and closely related α1‐adrenergic receptor antagonists (doxazosin [DZ] and alfuzosin [AZ]) enhance glycolysis and reduce neurodegeneration in animal models. Observational evidence in humans from several databases supports this finding; however, a recent study… read more here.
Keywords: use glycolysis; risk parkinson; parkinson disease; glycolysis enhancing ... See more keywords